Here are three highlights:
1. Attendees can trial the BoneScalpel and the BoneScalpel MIS.
2. The BoneScalpel MIS is intended to aid surgeons in minimally invasive procedures.
3. Misonix reported BoneScalpel global revenues increased 41 percent in the third quarter.
More articles on devices:
Opponents criticize associating research funds with FDA standards: 3 quick notes
Titan Spine makes an impact with nanotech spinal implants: 7 observations
FDA clears Orthofix’s FORZA PTC Interbody Spacer System: 5 highlights
